SGMC Health now offers PLUVICTO®, a cutting-edge therapy for men diagnosed with metastatic castration-resistant prostate cancer (mCRPC). This FDA-approved therapy represents a significant advancement in the fight against one of the most aggressive forms of prostate cancer.

PLUVICTO works by delivering a microscopic dose of radiation directly to cancer cells, minimizing harm to surrounding healthy tissue. The therapy is given through six IV infusions, spaced six weeks apart, and is available to patients who meet specific treatment criteria.

Paul Adedoyin, MD, Radiation Oncologist, recently administered the first PLUVICTO® therapy infusions to eligible patients at SGMC Health's Pearlman Cancer Center.

“This is a major step forward for cancer care in our region,” said Dr. Adedoyin. “PLUVICTO® offers new hope to patients whose prostate cancer has spread and no longer responds to hormone therapy. Being able to offer this treatment locally means patients don’t have to travel far to receive life-extending care.”

SGMC Health is also developing a theranostics program, a medical approach that combines diagnostics and therapy into a single, personalized treatment strategy, especially useful in cancer care. A key part of this initiative is the installation of a state-of-the-art Siemens PET scanner, which produces high-resolution scans to help physicians tailor treatments to each patient’s needs.

“This new technology and treatment option reflect our commitment to bringing world-class cancer care to South Georgia,” said Dr. Adedoyin. “We’re excited to offer patients in our community access to therapies that were previously only available in larger metropolitan areas.”

For more information on SGMC Health’s Pearlman Cancer Center, visit sgmc.org.